41 results
8-K
EX-99.1
IMGN
Immunogen, Inc.
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
because it contains a genotoxic compound (DM4) and affects actively dividing cells.
Advise pregnant women of the potential risk to a fetus. Advise females … concomitantly with strong CYP3A4 inhibitors.
USE IN SPECIAL POPULATIONS
Lactation
Advise women not to breastfeed during treatment with ELAHERE
8-K
EX-99.1
IMGN
Immunogen, Inc.
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ELAHERE … women not to breastfeed during treatment with ELAHERE and for at least 1 month after the last dose.
Pediatric Use
Safety and effectiveness of ELAHERE
8-K
EX-99.3
pgnkar0taks2 ojyltu
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
424B5
o70aj0x4kric6
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
s6z0eczrejxd0eo73
30 Nov 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
mpmrr9szi
30 Nov 21
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-99.1
25kc ifwpgq
11 Jan 21
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
lgtd0cgnj3rao 54
18 Dec 20
Other Events
4:16pm
424B5
fgll xrjj1zceqa
25 Sep 20
Prospectus supplement for primary offering
4:23pm
8-K
EX-99.1
v8mmzt
1 May 20
ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results
6:35am
424B5
vt16rombkcl
23 Jan 20
Prospectus supplement for primary offering
4:05pm